Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

References

• Roth BJ. Chemotherapy for advanced bladder cancer. Semin Oncol 1996; 23: 633–44
   PubMed Web of Science ®Google Scholar
• von der Maase H. Current and future perspectives in advanced bladder cancer: Is there a new standard?. Semin Oncol 2002; 29(1 Suppl 3)3–14
   PubMedGoogle Scholar
• Lohrer PJ, Einhorn LH, Elson P, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinome: A cooperative group study. J Clin Oncol 1992; 10: 1066–73
   PubMedGoogle Scholar
• Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000; 18: 3247–55
   PubMed Web of Science ®Google Scholar
• Stadler WM, Annamaria H, von der Maase H, Debasish R, Dogliotti L, Seymour L, et al. Long-term survival in phase II trials of gemcitabie plus cisplatin for advanced trasitional cell cancer. Urol Oncol 2002; 7: 153–7
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173–81
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95: 751–7
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066–73
   PubMed Web of Science ®Google Scholar
• Sengelov L, Kamby C, Geertsen P, Andersen LJ, von der Maase H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 2000; 46: 357–64
   PubMedGoogle Scholar
• Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001; 39: 634–42
   PubMedGoogle Scholar
• Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965; 130: 371–8
   PubMedGoogle Scholar
• Sobin LH, Fleming ID. TNM classification of malignant tumors. 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803–4
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO handbook for reporting results of cancer treatment. 48th ed. Geneva: WHO offset publication; 1979.
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Sengelov L, Nielsen OS, Kamby C, von der Maase H. Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. Cancer 1995; 76: 1797–803
   PubMed Web of Science ®Google Scholar
• Andersen LJ, Sengelov L, Kamby C, von der Maase H. Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer. Acta Oncol 1998; 37: 110–2
   PubMedGoogle Scholar
• von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 1999; 10: 1461–5
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068–77
   PubMed Web of Science ®Google Scholar
• von der Maase H, Geertsen PF, Baekke J, Daugaard G, Sengelov L, Pedersen D, et al. Gemcitabin, cisplatin and paclitaxel (GCP) as first-line treatment of locally advanced and metastatic cell carcinoma (TCC) of the urothelium. American Society of Clinical Oncology. Thirty-Ninth Annual Meeting 2003; 22: 410
   Google Scholar
• Nilsson S, Ragnhammer P, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in Urothelial bladder cancer. Acta Oncol 2001; 40: 371–90
   PubMedGoogle Scholar
• Ragnhammer P, Brorsson B, Nygren P, Glimelius B. A prospective study of the use of chemotherapy in Sweden and and assessment of the use in relation to scientific evidence. Acta Oncol 2001; 40: 391–411
   PubMedGoogle Scholar
• Mead GM, Russell M, Clark P, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a medical research council study. Br J Cancer 1998; 78: 1967–75
   Google Scholar